Insulin Biosimilars Market Analysis and Forecast 2016-2026 with Key Players Eli Lilly & Co., Boehringer Ingelheim, Merck & Co.: FMI Research Report
A new race has been initiated between biosimilar and branded drug manufacturers to gain maximum revenue share from insulin market. The upcoming three years are very crucial for insulin manufacturers, as most of the branded insulin are going to be off patent which would results into the loss of around US$53 Bn revenue for branded manufacturers in 2016. Generic manufacturers are expected to take smaller chunk of this amount owing to their local presence which would restrain them take share...
View full press release